Figure 3. Secondary End Points: Changes From Baseline in Patient-Reported Outcomes.

Analysis of covariance model including dose group and site as factors and the corresponding baseline value as a covariate. RIMA indicates rimabotulinumtoxinB. Error bars indicate the SE.

^aP < .05 vs placebo.

^bP < .01 vs placebo.

^cP < .001 vs placebo.